The latest update is out from Compass Therapeutics (CMPX).
On May 28, 2024, Compass Therapeutics, Inc. experienced a significant leadership change as Dr. Vered Bisker-Leib stepped down as CEO and Board member, with no disputes reported regarding company operations. She secured a Separation Agreement, including 18 months of salary and COBRA premiums, and a Consulting Agreement for 15 months with continued equity vesting. Concurrently, Dr. Thomas Schuetz was appointed the new CEO, bringing his expertise from his previous role as President of Research and Development. The company publicly announced these changes, emphasizing the smooth transition in its executive team.
For detailed information about CMPX stock, go to TipRanks’ Stock Analysis page.
